0. DOCID:30435 SCORE: 0.00379282411847839
DOCNO: 12206638
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: radiotherapy
AUTHOR: R Subramaniam R
AUTHOR: S J Arnott SJ
AUTHOR: M D Leslie MD
AFFILIATION: St Thomas' Hospital, London, UK.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical oncology (Royal College of Radiologists (Great Britain))
COUNTRY: England
TITLE: Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.
PUBDATE: 20020801
Repeat radical irradiation of the pelvis is generally not undertaken because of concerns regarding normal tissue damage; in particular to small bowel, bladder and bone. Two patients with carcinoma of the anal canal are presented who had previously been treated by radical pelvic radiotherapy for gynaecological malignancy. Both were re-treated with radical radiotherapy to the pelvis with concomitant chemotherapy. A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities.


1. DOCID:31112 SCORE: 0.00209937915449403
DOCNO: 12420862
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: chemically induced
QUALIFIER: pathology
AUTHOR: H M Turk HM
AUTHOR: C Camci C
AUTHOR: S Buyukberber S
AUTHOR: B Tuncozgur B
AUTHOR: C Sivrikoz C
AUTHOR: L Elbeyli L
AUTHOR: I Sari I
AFFILIATION: Gaziantep University, Faculty of Medicine, Department of Medical Oncology, Turkey.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of chemotherapy (Florence, Italy)
COUNTRY: Italy
TITLE: Superior vena cava syndrome caused by chemotherapy-induced fibrosis.
PUBDATE: 20020801
We report a case of a 51-year old man with small cell lung cancer who developed superior vena cava syndrome due to obstruction of the superior vena cava at the junction of the brachiocephalic vein by a fibrotic band, 2 months after completing six cycles of chemotherapy with cisplatin and etoposid. Superior vena cava syndrome caused by chemotherapy-induced pulmonary fibrosis should be kept in mind during follow-up.


2. DOCID:31409 SCORE: 0.00206372678254143
DOCNO: 14585261
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Drug Delivery Systems
QUALIFIER: classification
AUTHOR: Enrique Espinosa E
AUTHOR: Pilar Zamora P
AUTHOR: Jaime Feliu J
AUTHOR: Manuel González Barón M
AFFILIATION: Servicio de Oncología Médica, Hospital La Paz, Madrid, Spain. eespinosa00@terra.es
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer treatment reviews.
COUNTRY: England
TITLE: Classification of anticancer drugs--a new system based on therapeutic targets.
PUBDATE: 20031201
The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas monoclonal antibodies and small molecules are directed against proteins. The endothelium and extracellular matrix may be affected also by specific antibodies and small molecules.


3. DOCID:30145 SCORE: 0.00183146883988151
DOCNO: 16226700
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Epigenesis, Genetic
QUALIFIER: genetics
AUTHOR: Andrew P Feinberg AP
AFFILIATION: Department of Medicine, Johns Hopkins University School of Medicine, 1064 Ross, Baltimore, MD 21205, USA. afeinberg@jhu.edu
PUBTYPE: Journal Article
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: Cancer epigenetics is no Mickey Mouse.
PUBDATE: 20051001
Epigenetic changes are the most common alterations in human cancer, but it has been difficult to sort out cause and effect from studies of human tumors. Several recent nonlethal mouse models implicate both hypomethylation and loss of imprinting (LOI) in tumor formation, including a paper in this issue of Cancer Cell showing that transient hypomethylation in ES cells causes LOI and liver and intestinal tumors (). Hypomethylation appears to be a critical determinant of cancer, affecting chromosomal stability and specific gene targets.


4. DOCID:30968 SCORE: 0.00183020225678229
DOCNO: 14605452
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: J Lehmann J
AUTHOR: M Retz M
AUTHOR: M Hack M
AUTHOR: S Siemer S
AUTHOR: M Stöckle M
AFFILIATION: Klinik für Urologie und Kinderurologie, Universität des Saarlandes, Homburg, Deutschland.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: [Systemic chemotherapy for transitional cell carcinoma of the urothelium]
PUBDATE: 20031001
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy in the mid eighties of the past century clinically significant response rates as well as prolonged survival has been documented. This review summarizes seven Phase-III trials of systemic chemotherapy for advanced urothelial carcinoma as well as results from adjuvant and neoadjuvant Phase-III trials for muscle-invasive bladder cancer including the most recent reports.


5. DOCID:29865 SCORE: 0.00168634792720253
DOCNO: 15066236
OWNER: NLM
STATUS: MEDLINE
AUTHOR: Kanwaljit Mahal K
AUTHOR: Javier Hernandez J
AUTHOR: Joseph W Basler JW
AUTHOR: Ian M Thompson IM
AFFILIATION: Division of Urology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. hernandezj7@uthscsa.edu
PUBTYPE: Journal Article
JOURNALTITLE: Current oncology reports.
COUNTRY: United States
TITLE: What's New in the Field of Prostate Cancer Chemoprevention?
PUBDATE: 20040501
Chemoprevention trials for several malignancies are completed, planned, or underway. Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention. This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer.


6. DOCID:31586 SCORE: 0.0016110701016726
DOCNO: 12021543
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: methods
AUTHOR: Hiroyuki Matsue H
AUTHOR: Masahiro Kusuhara M
AUTHOR: Keiko Matsue K
AUTHOR: Akira Takashima A
AFFILIATION: Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-6069, USA. hiroyuki.matsue@utsouthwestern.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: International archives of allergy and immunology.
COUNTRY: Switzerland
TITLE: Dendritic cell-based immunoregulatory strategies.
PUBDATE: 20020401
Dendritic cells (DC) are special subsets of professional antigen-presenting cells that play a dual role in initiating and silencing acquired immune responses. Thus, it should be feasible to control the magnitude and direction of immune responses by experimental manipulation of DC function. We will provide an overview of the recent progress in the development of DC-based immunostimulatory and immunosuppressive strategies, which are potentially applicable to the treatment of cancer, allergy, autoimmune disease, allograft rejection and graft versus host disease.


7. DOCID:30543 SCORE: 0.00156176321801705
DOCNO: 12557698
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: blood
QUALIFIER: diagnosis
QUALIFIER: blood
AUTHOR: Hidetoshi Kuruma H
AUTHOR: Shin Egawa S
AFFILIATION: Dept. of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan.
PUBTYPE: Journal Article
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: Japan
TITLE: [Prostate-specific antigen and its related parameters in detecting prostate cancer]
PUBDATE: 20030101
Prostate-specific antigen (PSA) is the most useful tumor marker available today. However, its inability to clearly distinguish between prostate cancer and benign prostatic hyperplasia may result in serial and unnecessary prostate biopsies. Various attempts have been made to improve its specificity. PSA-related parameters including PSA density, PSA density for the transition zone, age- or race-specific PSA reference range, PSA velocity, and percent free PSA are the most promising approaches available at present.


8. DOCID:30717 SCORE: 0.00156103299908006
DOCNO: 15527808
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
AUTHOR: Jack S Mandel JS
AFFILIATION: Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA. jsmande@emory.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Medical clinics of North America.
COUNTRY: United States
TITLE: Screening of patients at average risk for colon cancer.
PUBDATE: 20050101
Both the incidence and the mortality from colorectal cancer can be substantially reduced by primary and secondary prevention. There are many screening tests for colorectal cancer, and any test should result in a reduction in colorectal cancer incidence and mortality. If the age-eligible population undergoes these screening tests, the burden of colorectal cancer should be substantially reduced. The scientific evidence related to secondary prevention, specifically screening of individuals at average risk for colorectal cancer, is presently reviewed.


9. DOCID:30652 SCORE: 0.00153797504153472
DOCNO: 12611113
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: prevention & control
QUALIFIER: methods
AUTHOR: Kim Cardenas K
AUTHOR: Kelly Frisch K
AFFILIATION: Department of Internal Medicine, Regions Hospital, 451 N Dunlap St, St Paul, MN 55104, USA. kim.k.cardenas@healthpartners.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Postgraduate medicine.
COUNTRY: United States
TITLE: Comprehensive breast cancer screening. Programs now include individual risk assessment.
PUBDATE: 20030201
A comprehensive breast cancer screening program needs to include risk assessment in addition to clinical breast examination and mammography. Women identified as being at increased risk should have an individualized schedule of screening mammography and a proven prevention program tailored to their level of risk. In this article, Drs Cardenas and Frisch review risk factors, screening methods, and individual risk assessment, then explain how to use them in conjunction to identify tumors at an earlier, more curable stage.


10. DOCID:30744 SCORE: 0.00151705571888693
DOCNO: 14598211
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Boehmeria
DESCRIPTOR: Phytotherapy
QUALIFIER: pharmacology
QUALIFIER: pharmacology
AUTHOR: Yinggang Luo Y
AUTHOR: Yan Liu Y
AUTHOR: Dixiang Luo D
AUTHOR: Xiaoping Gao X
AUTHOR: Bogang Li B
AUTHOR: Guolin Zhang G
AFFILIATION: Chengdu Institute of Biology, the Chinese Academy of Sciences, Chengdu 610-041, P. R. China.
PUBTYPE: Journal Article
JOURNALTITLE: Planta medica.
COUNTRY: Germany
TITLE: Cytotoxic alkaloids from Boehmeria siamensis.
PUBDATE: 20030901
Two new phenanthroquinolizidine alkaloids, boehmeriasins A and B, were isolated from the aqueous ethanolic extract of Boehmeria siamensis Craib (Urticaceae) by bioassay-guided fractionation. Their structures were elucidated on the basis of spectral evidence. Boehmeriasin A possesses cytotoxic activity against 12 cell lines from 6 panels of cancer including lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer and leukemia with GI (50) between 0.2 and 100 ng/mL, whereas boehmeriasin B showed lower activity.


11. DOCID:30780 SCORE: 0.00151705496290922
DOCNO: 14716138
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: adverse effects
AUTHOR: G von Minckwitz G
AFFILIATION: German Breast Group, Frankfurt/M. minckwitz@germanbreastgroup.de
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: [Taxanes in primary systemic treatment of breast cancer]
PUBDATE: 20031201
Primary systemic treatment today represents a new option for patients with operable breast cancer and is equally effective as conventional adjuvant chemotherapy. Improving surgical options is the most important indication for choosing this approach. The highest chance for breast conserving surgery can be obtained when a sequence of adriamycin and cyclophosphamide (AC) is followed by docetaxel. This has been shown in the Geparduo and NSABP-B27 trial. New approaches are considering individual tailoring of treatment according to either early response of the primary breast tumor (Gepartrio) or pharmacogenetic testing on the tumor tissue.


12. DOCID:29451 SCORE: 0.00149391087725043
DOCNO: 12085251
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genetic Predisposition to Disease
DESCRIPTOR: SEER Program
DESCRIPTOR: Translocation, Genetic
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: X Bu X
AUTHOR: L Bernstein L
AUTHOR: R K Brynes RK
AFFILIATION: Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA.
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: Scotland
TITLE: Reduced risk of synovial sarcoma in females: X-chromosome inactivation?
PUBDATE: 20020701
Synovial sarcoma shows a characteristic t(X;18) translocation but not the expected female predominance in incidence. We speculate that, among females, one X-chromosome is inactivated and that only the translocation to an active X-chromosome leads to development of synovial sarcoma. Population-based cancer registry data from the SEER program support this hypothesis.


13. DOCID:31864 SCORE: 0.0014565358513843
DOCNO: 16224168
OWNER: NLM
STATUS: In-Process
AUTHOR: Sung Ho Song SH
AUTHOR: Ick Jang I
AUTHOR: Bum Sik Kim BS
AUTHOR: Eun Tak Kim ET
AUTHOR: Seung-Hyo Woo SH
AUTHOR: Mee Ja Park MJ
AUTHOR: Chang Nam Kim CN
AFFILIATION: Department of Urology, Eulji Medical University, Daejeon, Korea.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of Korean medical science.
COUNTRY: Korea (South)
TITLE: A case of primary syphilis in the rectum.
PUBDATE: 20051001
A 30-yr-old man was referred for suspicious rectal cancer because of ulcerated lesions in the rectum and a palpable mass in left inguinal area. Sigmoidoscopy showed two indurated masses and histologic evaluation of biopsy revealed obliterative endarteritis with heavy plasma cell infiltration. Both venereal disease research laboratories (VDRL) and fluorescent treponemal antibody absorption (FTA-ABS) tests were positive. After injection of penicillin G benzathine for 3 weeks, the rectal chancre and the palpable mass disappeared.


14. DOCID:29810 SCORE: 0.00129203243591301
DOCNO: 14605451
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: S Krege S
AFFILIATION: Urologische Universitätsklinik Essen, Deutschland.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: [Chemotherapy of advanced urological tumors]
PUBDATE: 20031001
The indication for chemotherapy is quite different in urological malignancies. In case of testicular tumors the availability of chemotherapy is one of the milestones in their successful treatment. Patients with low-volume metastases will be cured in nearly 100% and even far advanced disease can be cured in more than 50%. Contrarily in renal cell carcinoma chemotherapy is without any significance, response rates are <8%. Comparable is the situation in penile cancer. Though in hormone-refractory prostate cancer chemotherapy also can not prevent further disease progression, it shows good palliative effects.